Abstract
Checkpoint kinase 2 is a serine/threonine protein which functions as an important transducer in apoptosis or DNA repair following activation by DNA damage. Inhibition of checkpoint kinase 2 is thought to sensitize p53-mutated or p53-deficient cancerous cells but protect normal tissue following DNA-damage caused by ionizing radiation or chemotherapeutic agents. The development of checkpoint kinase inhibitors for the treatment of cancer has therefore been a major objective in drug discovery over the past decade. Several inhibitors have been co-crystallized in the active site of checkpoint kinase 2 revealing important features of effective inhibitors. Some of these inhibitors have entered clinical trials in the last decade. This review describes and discusses the most recent inhibitors of checkpoint kinase 2 as reported in the literature, including an evaluation of biological activity.
Keywords: Checkpoint kinase 2, chemotherapy, kinase inhibitors, DNA, DNA-damage, ionizing radiation, chemotherapeutic agents, cancer, serine/threonine protein, biological activity
Current Medicinal Chemistry
Title: Current Inhibitors of Checkpoint Kinase 2
Volume: 18 Issue: 28
Author(s): T. N.T. Nguyen and J. J. Tepe
Affiliation:
Keywords: Checkpoint kinase 2, chemotherapy, kinase inhibitors, DNA, DNA-damage, ionizing radiation, chemotherapeutic agents, cancer, serine/threonine protein, biological activity
Abstract: Checkpoint kinase 2 is a serine/threonine protein which functions as an important transducer in apoptosis or DNA repair following activation by DNA damage. Inhibition of checkpoint kinase 2 is thought to sensitize p53-mutated or p53-deficient cancerous cells but protect normal tissue following DNA-damage caused by ionizing radiation or chemotherapeutic agents. The development of checkpoint kinase inhibitors for the treatment of cancer has therefore been a major objective in drug discovery over the past decade. Several inhibitors have been co-crystallized in the active site of checkpoint kinase 2 revealing important features of effective inhibitors. Some of these inhibitors have entered clinical trials in the last decade. This review describes and discusses the most recent inhibitors of checkpoint kinase 2 as reported in the literature, including an evaluation of biological activity.
Export Options
About this article
Cite this article as:
N.T. Nguyen T. and J. Tepe J., Current Inhibitors of Checkpoint Kinase 2, Current Medicinal Chemistry 2011; 18 (28) . https://dx.doi.org/10.2174/092986711797200390
DOI https://dx.doi.org/10.2174/092986711797200390 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vector Delivery Methods and Targeting Strategies for Gene Therapy of Brain Tumors
Current Gene Therapy Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment
Current Drug Delivery WISP1 (CCN4) Autoregulates its Expression and Nuclear Trafficking of β-Catenin during Oxidant Stress with Limited Effects upon Neuronal Autophagy
Current Neurovascular Research Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Current Vascular Pharmacology Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to "Work it Out"?
Current Pharmaceutical Design Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors
Current Gene Therapy Biomacromolecule-Functionalized Nanoparticle-Based Conjugates for Potentiation of Anticancer Therapy
Current Cancer Drug Targets Entropy and Enthalpy in the Activity of Tubulin-Based Antimitotic Agents
Current Chemical Biology Recent Developments in the Chemical Biology of Epothilones
Current Pharmaceutical Design Sigma Receptors and Cocaine Abuse
Current Topics in Medicinal Chemistry CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design What Makes Y Family Pols Potential Candidates for Molecular Targeted Therapies and Novel Biotechnological Applications
Current Molecular Medicine Intracellular Calcium, Endothelial Cells and Angiogenesis
Recent Patents on Anti-Cancer Drug Discovery Oleuropein Mediated Targeting of Signaling Network in Cancer
Current Topics in Medicinal Chemistry Pannexin Channels: The Emerging Therapeutic Targets
Current Drug Targets Summary of Information on the Effects of Ionizing and Non-ionizing Radiation on Cytochrome P450 and Other Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism Passive and Active Tumour Targeting with Nanocarriers
Current Drug Discovery Technologies